Bristol-Myers Squibb Option Alert: Jan 16 $55 Puts at the Bid: 1000 vs 2166 OI

Bristol-Myers Squibb Option Alert: Jan 16 $55 Puts at the Bid: 1000 @ $5.5 vs 2166 OI; Ref=$54.76

Bristol-Myers Squibb (NYSE:BMY) 주식

BRISTOL-MYERS SQUIBB CO

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Fear and Greed

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AMZN

NVDA

TSLA

CNN 머니 공포·탐욕 지수는 시장 심리에 일부 개선을 나타냈지만, 목요일(24일) 여전히 &#34;공포&#34; 영역에 머물렀다. 미국 주식은 목요일에 상승세로 마감했으며, 다우존스 지수는 장중 1% 이상 급등해 4월 15일 이후 처음으로 40,000포인트 수준을 넘었다.

엔비디아·테슬라 상승 속 S&amp;P 500 2% 올랐으나, 탐욕 지수는 여전히 &#39;공포&#39; 영역

GOOGL

CNN 머니의 공포·탐욕 지수는 시장 심리에 약간의 개선을 보였으며, 수요일(23일) 지수가 &#34;공포&#34; 영역에 있었다.미국 주식은 수요일 상승 마감했으며, 다우존스 지수는 거래 세션 중 400포인트 이상 급등했다. 그러나 세 개의 주요 지수 모두 세션 종료 시점에 고점에서는 상당히 하락한 상태로 마감했다. 다우는 오전 세션 중 한때 1,100포인트 이상 급등하기도 했다.

대중국 관세 완화 기대 속 다우 지수 400p 상승: 투자자 불안 완화, 탐욕 지수는 &#39;공포&#39; 영역에

In,This,Photo,Illustration,,The,New,Pepsi,Logo,On,A

목요일(24일) 아침 미국 지수 선물이 하락세로 거래되고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 브리스톨 마이어스, 노키아, 펩시코, 프록터앤드갬블 및 알파벳

목요일 주목해야 할 주식: 브리스톨 마이어스, 노키아, 펩시코, 프록터앤드갬블 및 알파벳

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">American consumers and patients</a>.
This change builds upon the agency&#8217;s Office of Inspection and Investigations&#8217; Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies.&nbsp;
&#8220;For too long, foreign companies have enjoyed a double standard—given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such warning,&#8221; said FDA Commissioner Martin Makary. &nbsp;
On Tuesday, the FDA <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities?utm_medium=email&amp;utm_source=govdelivery" rel="noreferrer noopener">said</a> it plans to review and improve its foreign inspection program to ensure it meets the highest standards for oversight. Part of this effort includes making it clear that FDA inspectors should not accept travel-related perks like hotel stays or transportation from the companies they inspect.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45225204/iqvia-beats-q1-earnings-expectations-despite-sector-uncertainty-company-navigating-market-conditions-effectively-says-ceo" rel="noreferrer noopener">IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions &#8216;Effectively&#8217; Says CEO</a>
The FDA conducts about 12,000 inspections annually in the U.S. and 3,000 in other countries. While U.S. companies often get surprise inspections, foreign companies usually receive advanced notice, giving them time to prepare and potentially hide problems.
Still, foreign inspections often reveal serious issues, more than twice as often as domestic ones.
In the U.S., inspections are usually unannounced unless specific programs require advance notice to ensure staff and records are available.
Even then, companies can&#8217;t pick the date or time. The FDA says foreign companies shouldn&#8217;t have that option either.
By shifting to more surprise inspections abroad, the FDA aims to better protect American consumers by catching dishonest practices, like falsifying records or hiding violations, before they cause harm.
The agency can take action against any company that tries to delay, block, or refuse an unannounced inspection.
The update follows President&nbsp;Donald Trump&#8217;s signed executive order on Monday to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The order directs the FDA to reduce the amount of time it takes to approve manufacturing plants in the U.S. by eliminating unnecessary requirements, streamlining reviews, and working with domestic drugmakers to &#8220;provide early support before facilities come online,&#8221; <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-reduce-regulatory-barriers-to-domestic-pharmaceutical-manufacturing/" rel="noreferrer noopener">according</a> to&nbsp;a White House fact sheet.
It also directs the agency to raise inspection fees for foreign manufacturing plants, improve the enforcement of active-ingredient source reporting by overseas producers, and consider publicly listing facilities that don&#8217;t comply.
The White House <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/" rel="noreferrer noopener">estimates</a> that it can currently take five to ten years to build new pharmaceutical manufacturing capacity, which it calls &#8220;unacceptable from a national-security standpoint.&#8221;
<a target="_blank" href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs" rel="noreferrer noopener">Amid tariff uncertainty</a>, many companies have disclosed a wave of investments in recent months to boost production in the U.S.
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest $2.5 billion in U.S. manufacturing capacity <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) did not highlight investments in new manufacturing plants; it noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">their products in the U.S</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Most recently, Bristol-Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer, <a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/" target="_blank" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Stat this week.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45195137/footwear-titans-nike-adidas-call-tariffs-an-existential-threat-appeal-to-trump-for-relief-this-is-an-emergency" target="_blank" rel="noreferrer noopener">Footwear Titans Nike, Adidas Call Tariffs An &#8216;Existential Threat&#8217;, Appeal To Trump For Relief: &#8216;This Is An Emergency&#8217;</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Government

Large Cap

Regulations

Health Care

General

REGN

RHHBY

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 5.59%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and cut the price target from $14 to $10 on March 5, 2025. This analyst has an accuracy rate of 73%.</li>
<li>B of A Securities analyst Jason Gerberry maintained an Underperform rating and slashed the price target from $11 to $10 on Feb. 28, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On April 14, Viatris named Hemanth J. Varghese as Chief Strategy Officer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">VTRS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="918" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png" alt="" class="wp-image-902820" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-768x701.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.95%</li>
<li>Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $65 on April 22, 2025. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and slashed the price target from $60 to $54 on April 11, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="907" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png" alt="" class="wp-image-902821" style="width:561px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-768x714.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 4.10%</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and cut the price target from $20 to $19 on Feb. 5, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: The company is expected to announce quarterly earnings today.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest PINC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="906" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png" alt="" class="wp-image-902822" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-768x714.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Dividends

Price Target

Analyst Ratings

PINC

VTRS

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>)&nbsp;aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26 <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">from September 26</a>.
The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company's proposed Risk Evaluation and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Mitigation Strategy (REMS)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach</a>
Following pre-NDA discussions with the FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for&nbsp;aficamten in oHCM without an accompanying REMS, and the FDA <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45150594/cytokinetics-announces-new-pdufa-date-for-aficamten-in-obstructive-hypertrophic-cardiomyopathy" rel="noreferrer noopener">accepted the NDA for filing</a>.
Recently, during the NDA review, the FDA requested that Cytokinetics submit a REMS, based on the inherent characteristics of&nbsp;aficamten, which the company provided.
The submission of a REMS has now been determined by FDA to be a Major Amendment to the NDA resulting in a standard three-month extension to the original PDUFA action date.
No additional clinical data or studies have been requested on Cytokinetics by the FDA.
"We remain confident in the distinct benefit-risk and pharmaceutic profile of&nbsp;aficamten and continue to expect a differentiated label and risk mitigation profile upon its potential approval by FDA," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "
In April, Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) released topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos&nbsp;(mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44825297/why-us-pharma-giant-bristol-myers-squibb-stock-trading-lower-on-tuesday" rel="noreferrer noopener">hypertrophic cardiomyopathy (nHCM)</a>.
The trial did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) and peak oxygen&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44801468/bristol-myers-squibb-provides-update-on-phase-3-odyssey-hcm-trial" rel="noreferrer noopener">consumption (pVO2)</a>.
In January, a Stifel analyst wrote that Cytokinetics appears well-positioned to capitalize on Bristol Myers' groundwork with its second-to-market drug, Alicante, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms <a target="_blank" href="https://www.benzinga.com/25/01/43143013/analyst-optimistic-about-cytokinetics-heart-drugs-future-despite-ma-hurdles-and-royalty-deal-concerns" rel="noreferrer noopener">(Q6M echos) as a standard</a>.
Price Action: CYTK stock is down 16.5% at $35.85 at the last check Friday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45168310/astrazenecas-triple-combination-therapy-breztri-hits-primary-goals-in-two-pivotal-studies-for-asthma" target="_blank" rel="noreferrer noopener">AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma</a></li>
</ul>

Movers

CYTK

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

<a href="https://www.gov.uk/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes#:~:text=The%20subcutaneous%20formulation%20of%20nivolumab,and%20head%20and%20neck%20cancers" title="https://www.gov.uk/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes#:~:text=The%20subcutaneous%20formulation%20of%20nivolumab,and%20head%20and%20neck%20cancers">https://www.gov.uk/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes#:~:text=The%20subcutaneous%20formulation%20of%20nivolumab,and%20head%20and%20neck%20cancers</a>.

MHRA Authorizes Cancer Treatment Variation With An Administration Time Of 3–5 Minutes; Approved New Under-The-Skin Injection Version Of Nivolumab (Opdivo)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</h3>
<ul>
<li>On April 21, UnitedHealth reported worse-than-expected first-quarter results and cut its FY25 adjusted EPS guidance below estimates. "UnitedHealth Group grew to serve more people more comprehensively but did not perform up to our expectations, and we are aggressively addressing those challenges to position us well for the years ahead, and return to our long-term earnings growth rate target of 13 to 16%," said Andrew Witty, CEO of UnitedHealth. The company's stock fell around 19% over the past month and has a 52-week low of $412.02.</li>
<li>RSI Value: 27.1</li>
<li>UNH Price Action: Shares of UnitedHealth fell 1.3% to close at $418.64 on Friday.</li>
<li>Edge Stock Ratings: 26.37 Momentum score with Value at 69.10. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/UNH"><img loading="lazy" decoding="async" width="481" height="192" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186.png" alt="" class="wp-image-890598" style="width:331px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186.png 481w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186-300x120.png 300w" sizes="(max-width: 481px) 100vw, 481px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;&nbsp;</h3>
<ul>
<li>On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion. &#8220;Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline,&#8221; said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. The company's stock fell around 20% over the past month and<a href="https://www.benzinga.com/quote/BMY"> has a 52-week low</a> of $39.35.</li>
<li>RSI Value: 25</li>
<li>BMY Price Action: Shares of Bristol-Myers Squibb dipped 1.6% to close at $47.90 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">BMY stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="916" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187.png" alt="" class="wp-image-890615" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187-768x710.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">X4 Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>)</h3>
<ul>
<li>On April 24, X4 Pharmaceuticals company announced a 1-for-30 reverse stock split. The company has a 52-week <a href="https://www.benzinga.com/quote/XFOR">low of $0.17.</a></li>
<li>RSI Value: 14.7</li>
<li>XFOR Price Action: Shares of X4 Pharmaceuticals closed at $5.70 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">XFOR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="876" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188.png" alt="" class="wp-image-890619" style="width:566px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188.png 876w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188-768x737.png 768w" sizes="(max-width: 876px) 100vw, 876px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

XFOR

Top 3 Health Care Stocks That May Rocket Higher In April

The CNN Money Fear and Greed index some improvement in market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the Dow Jones index jumping more than 1% during the session to mark the first close above the 40,000 level since April 15.
Shares of Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) all settled higher on Thursday.
Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) reported better-than-expected first-quarter results. PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) reported mixed first-quarter results and issued FY25 EPS guidance below estimates.
Meanwhile, signs of a potential thaw in the U.S.-China trade conflict emerged, with the White House reportedly considering exceptions for certain Chinese auto parts.
On the economic data front, the Chicago Fed National Activity Index declined to -0.03 in March compared to a reading of +0.24 in February. U.S. initial jobless claims climbed by 6,000 from the previous week to 222,000 during the third week of April. U.S. durable goods orders gained by 9.2% month-over-month to $315.7 billion in March.
Most sectors on the S&amp;P 500 closed on a positive note, with information technology, consumer discretionary and communication services stocks recording biggest gains on Thursday. However, consumer staples stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 487 points to 40,093.40 on Thursday. The S&amp;P 500 jumped 2.03% to 5,484.77, while the Nasdaq Composite surged 2.74% at 17,166.04 during Thursday's session.
Investors are awaiting earnings results from Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) and Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) today.
At a current reading of 30.9, the index remained in the &#8220;Fear&#8221; zone on Thursday, versus a prior reading of 28.4.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based
&nbsp;on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44977071/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

S&P 500 Rallies 2% On Nvidia, Tesla Gains — But Market Mood Stuck In 'Fear'

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Thursday.
The Dow traded up 0.97% to 39,989.57 while the NASDAQ gained 2.24% to 17,082.79. The S&amp;P 500 also rose, gaining, 1.69% to 5,466.54.
Check This Out: <a href="https://www.benzinga.com/25/04/44947241/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Information technology shares jumped by 2.5% on Thursday.
In trading on Thursday, consumer staples fell by 1.2%.
Top Headline
Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) reported better-than-expected first-quarter results.
The company posted quarterly revenues of $11.20 billion, beating the consensus of $10.70 billion. The company reported an adjusted EPS of $1.80, a turnaround from a loss of $4.40 a year ago, beating the consensus of $1.49.
Bristol Myers Squibb raised its fiscal year 2025 adjusted EPS from $6.55-$6.85 to $6.70-$7.00 compared to consensus of $6.74.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares shot up 24% to $3.0250 after the company reported better-than-expected first-quarter financial results.</li>
<li>Shares of TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>)got a boost, surging 34% to $3.4255 following a Reuters report indicating President Trump is expected to sign an executive order to advance the deep sea mining industry.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares were also up, gaining 32% to $1.05 after the company announced the key clinical trial site location for its Phase 1 CER-1236 trial.</li>
</ul>
Equities Trading DOWN
<ul>
<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) shares dropped 16% to $9.18 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Shares of Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) were down 16% to $181.90 after the company issued FY25 adjusted EPS guidance with its midpoint below estimates.</li>
<li>ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) was down, falling 15% to $49.78 following weaker-than-expected quarterly earnings.</li>
</ul>
Commodities In commodity news, oil traded up 0.3% to $62.48 while gold traded up 1.1% at $3,330.70.
Silver traded down 0.6% to $33.355 on Thursday, while copper fell 0.1% to $4.8395.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.36%, Germany's DAX 40 gained 0.49% and France's CAC 40 gained 0.26%. Spain's IBEX 35 Index fell 0.40%, while London's FTSE 100 rose 0.05%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 surging 0.49%, China's Shanghai Composite gaining 0.03%, Hong Kong's Hang Seng Index falling 0.74% and India's BSE Sensex falling 0.39%.
Economics
<ul>
<li>U.S. natural-gas stocks increased 88 billion cubic feet during the week ending April 18, compared to market estimates of 65 bcf gain.</li>
<li>U.S. existing home sales fell by 5.6% from the previous month to an annualized rate of 4.02 million units in March.</li>
<li>The Chicago Fed National Activity Index declined to -0.03 in March compared to a reading of +0.24 in February.</li>
<li>U.S. initial jobless claims climbed by 6,000 from the previous week to 222,000 during the third week of April.</li>
<li>U.S. durable goods orders gained by 9.2% month-over-month to $315.7 billion in March.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44976958/jim-cramer-arista-networks-is-down-way-too-much-likes-uber-very-much">Jim Cramer: Arista Networks Is &#8216;Down Way Too Much,&#8217; Uber &#8216;Goes Higher&#8217;</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

ASGN

CERO

Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results

U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade <a href="https://www.benzinga.com/markets">tensions boosts risk sentiment.</a>
Positive quarterly results and robust guidance from U.S. firms is fueling hopes the economy can weather the ongoing tariff headwinds and avoid a recession.
Meanwhile, signs of a potential thaw in the U.S.-China trade conflict emerged, with the White House reportedly considering exceptions for certain Chinese auto parts.
At midday trading in New York, the Nasdaq 100 surged 2.2%, climbing above the 19,000 mark for the first time in two weeks. The S&amp;P 500 advanced 1.5%, while the Dow Jones Industrial Average underperformed, rising 0.9%.
Technology stocks broadly outperformed, with strength concentrated in the Magnificent Seven and the semiconductor space.
Among major movers, ServiceNow Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>) soared 15% after reporting results that beat Wall Street expectations and issuing bullish forward guidance. In contrast, shares of International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) slumped 8% as the tech giant showed lower-than-expected non-GAAP earnings. 
In the consumer staples sector, Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) dropped more than 5% after missing revenue estimates.
Treasury yields continued to ease, with yields on the 10-year Treasury down 5 basis points to 4.33%. 
Gold rebounded modestly after suffering a 2.7% slide on Wednesday. Natural gas prices extended their losing streak, plunging 4.9% and heading for a tenth consecutive negative session. 
In the crypto market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) eased 0.5% to trade at $93,300. 
<h2 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,095.73</td>
<td>2.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,456.36</td>
<td>1.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,943.95</td>
<td>1.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,944.47</td>
<td>0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.5% up to $543.71.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.9% to $399.51.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 2.1% to $464.72.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.5% to $193.08.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 3%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 0.8%.</li>
</ul>
<h2 class="wp-block-heading">Thursday&#8217;s Stock Movers</h2>
Stocks reacting to earnings included: 
<ul>
<li>Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>): up 0.6%</li>
<li>O'Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>): down 3.1%</li>
<li>Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>): up 0.7%</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>): down 6.4%</li>
<li>Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>): up 6.0%</li>
<li>FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>): up 0.4%</li>
<li>ServiceNow, Inc. up 14.9%</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>): up 5.5%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>): up 10.0%</li>
<li>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>): up 3.6%</li>
<li>International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): down 7.6%</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>): up 3.6%</li>
<li>Rollins, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>): up 1.2%</li>
<li>United Rentals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>): up 8.9%</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>): down 3.0%</li>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 7.1%</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>): up 5.2%</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>): down 9.7%</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>): up 2.3%</li>
<li>PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): down 4.1%</li>
<li>CBRE Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>): up 2.5%</li>
<li>Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): up 0.4%</li>
<li>The Procter &amp; Gamble Company: down 5.3%</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>): down 0.2%</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>): down 0.2%</li>
<li>Valero Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>): down 1.8%</li>
<li>Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): down 5.3%</li>
<li>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>): up 2.1%</li>
<li>Willis Towers Watson Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>): down 5.2%</li>
<li>Tractor Supply Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>): down 4.8%</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>): up 16.1%</li>
<li>CMS Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>): up 2.3%</li>
<li>Xcel Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>): down 1.8%</li>
<li>CenterPoint Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>): up 1.8%</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>): down 10.7%</li>
<li>PG&amp;E Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>): down 0.8%</li>
<li>Keurig Dr Pepper Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>): down 0.6%</li>
<li>Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>): up 5.5%</li>
<li>Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): down 0.6%</li>
<li>Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>): down 0.4%</li>
<li>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>): up 0.4%</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>): down 6.1%</li>
<li>Dover Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>): up 1.8%</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>): down 2.2%</li>
<li>Ameriprise Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>): down 0.2%</li>
<li>Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): down 16.4%</li>
<li>The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>): up 3.4%</li>
<li>Allegion plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>): up 9.7%</li>
<li>Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>): down 3.1%</li>
</ul>
Stocks slated to report earnings after the bell include T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>), Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), Principal Financial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>), Physicians Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), The Hartford Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>), Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>), Republic Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>), Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>).
Read also: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44985682/apples-ai-delays-rising-cost-pressures-trigger-price-target-cut-from-bank-of-america">Apple AI Delays, Rising Cost Pressures Trigger Price Target Cut From Bank Of America</a></li>
</ul>
Photo: Shutterstock

Analyst Color

$BTC

ALLE

CBRE

CMCSA

SPDR Dow Jones Industrial Average ETF Trust

ERIE

GILD

INTC

LRCX

NDAQ

ORLY

POOL

TMUS

TSCO

VRSN

Select Sector SPDR-Consumer Discretionary

Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?

Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44974906/bristol-myers-squibb-reports-first-quarter-financial-results-for-2025" rel="noreferrer noopener">first-quarter 2025 revenues</a> of $11.20 billion, beating the&nbsp;consensus of $10.70 billion.
Sales decreased 6% year-over-year, or 4% when adjusted for foreign exchange impacts.
U.S. revenues of $7.9 billion decreased by 7%, and International revenues of $3.3 billion decreased by 2% or increased by 2% Ex-FX.
Growth Portfolio revenues reached $5.6 billion, up 16% on a reported basis (18% Ex-FX), primarily driven by Opdivo, Breyanzi, Reblozyl, and Camzyos and reflected the strong early U.S. launch of Cobenfy.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44950727/bristol-myers-cobenfy-falls-short-on-primary-endpoint-in-phase-3-schizophrenia-trial" rel="noreferrer noopener">Bristol Myers&#8217; Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides</a>
Sales of the cancer drug Opdivo increased 9% to $2.265 billion. The arthritis drug Orencia generated sales of $770 million, down 4%. Sales of another cancer drug, Yervoy, increased 7% to $624 million.
The anemia drug Reblozyl generated $478 million in quarter sales, up 35% from a year ago.
Legacy Portfolio revenues of $5.6 billion declined 20% on a reported basis and Ex-FX due to the generic impact on Revlimid, Pomalyst, Sprycel, and Abraxane and&nbsp;the impacts from the U.S. Medicare Part D redesign.
The company reported an adjusted EPS of $1.80, a turnaround from a loss of $4.40 a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.49</a>.
Gross margin decreased from 75.3% to 72.9% on a GAAP basis and from 75.5% to 73.1% on a non-GAAP basis, primarily due to product mix.
Guidance:&nbsp;Bristol Myers Squibb has raised its fiscal year 2025 adjusted EPS <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43528698/bristol-myers-squibb-warns-near-term-impact-due-to-generics-on-2025-sales-forecast-outlines-2-billion-in-additional-cost-cuts" rel="noreferrer noopener">from $6.55-$6.85</a> to $6.70-$7.00 compared to consensus of $6.74.
On Thursday, the company stated that guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China but do not account for potential pharmaceutical sector tariffs.
The U.S. drug giant also raised the 2025 sales guidance from $45.50 billion to $45.80 billion—$46.80 billion, compared to the consensus of $45.76 billion.
The increased guidance reflects the strong performance of the Growth Portfolio, better-than-expected Legacy Portfolio sales in the first quarter of 2025, and a favorable impact of approximately $500 million related to foreign exchange rates.
Price Action: BMY stock is down 0.54% at $48.27&nbsp;at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44978234/intel-autonomous-driving-firm-mobileye-reaffirms-2025-outlook-after-record-q1-growth-in-system-shipments-and-design-wins" target="_blank" rel="noreferrer noopener">Intel Autonomous Driving Firm Mobileye Reaffirms 2025 Outlook After Record Q1 Growth</a></li>
</ul>
Photo via Shutterstock

Guidance

Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact

Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) raises FY2025 Adj EPS guidance from $6.55-$6.85 to $6.70-$7.00 vs $6.74 analyst estimate. Raises FY2025 sales outlook from $45.50 billion to $45.80 billion-$46.80 billion vs $45.76 billion estimate.

Bristol-Myers Squibb Raises FY2025 Adj EPS Guidance from $6.55-$6.85 to $6.70-$7.00 vs $6.74 Est; Raises FY2025 Sales Guidance from $45.50B to $45.80B-$46.80B vs $45.76B Est

Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.49 by 20.81 percent. This is a 140.91 percent increase over losses of $(4.40) per share from the same period last year. The company reported quarterly sales of $11.20 billion which beat the analyst consensus estimate of $10.70 billion by 4.70 percent. This is a 5.60 percent decrease over sales of $11.87 billion the same period last year.

Earnings Beats

Bristol-Myers Squibb Q1 Adj. EPS $1.80 Beats $1.49 Estimate, Sales $11.20B Beat $10.70B Estimate

U.S. stock futures fell on Thursday after a two-day advance. Futures of major benchmark indices were lower in premarket.
The administration&#8217;s mixed signals on tariffs fueled investor anxiety. While President Donald Trump hinted at a deal with China while speaking to reporters on Tuesday after market hours, the Treasury Secretary Scott Bessent <a href="https://www.benzinga.com/markets/equities/25/04/44970416/scott-bessents-china-de-escalation-scoop-delivered-to-wall-street-early-at-closed-door-event-2-2-trillion-in-gains-later-questions-arise-if-retail-investors-were">denied slashing steep tariffs</a> on Chinese imports unilaterally on Wednesday. China<a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis"> also refuted Trump&#8217;s trade talk</a> assertion.
Investors will also keep an eye on tech giant and Google&#8217;s parent Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) slated to be released later today.
Meanwhile, the 10-year Treasury bond yielded 4.35% and the two-year bond was at 3.83%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool&#8217;</a>s projections show markets pricing a 93.9% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.72%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.59%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.86%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.57%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Thursday. The SPY was down 0.51% to $532.67, while the QQQ declined 0.71% to $451.33, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Information technology, consumer discretionary, and communication services sectors led U.S. stocks higher Wednesday, with the Dow Jones jumping over 400 points, though all major indices <a href="https://www.benzinga.com/news/earnings/25/04/44972538/dow-jumps-over-400-points-amid-china-tariff-hopes-investor-fear-eases-greed-index-remains-in-fear-zone">closed well below their session highs</a> after the Dow had surged over 1,100 points earlier.
Most S&amp;P 500 sectors closed positively, but consumer staples and energy stocks finished the session lower.
Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) reported strong first-quarter results and raised its FY25 adjusted EPS outlook, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained over 5% after its first-quarter earnings release.
Economic data showed new single-family home sales rose 7.4% to an annualized 724,000, the S&amp;P Global services PMI fell to 51.4 in April, and the manufacturing PMI increased to 50.7.
As of Wednesday, the Nasdaq 100 index was down 15.88% from its previous high of 22,222.61 points. The S&amp;P 500 index was 12.55% lower, as compared to the last record high of 6,147.43 points. On the other hand, Dow Jones was 12.13% down from its 52-week high of 45,073.63 points.
The Dow Jones index jumped 420 points or 1.07% to 39,606.57, whereas the S&amp;P 500 index surged 1.67% to 5,375.86. Nasdaq Composite ended 2.50% higher at 16,708.05, and the small-cap gauge, Russell 2000, also advanced 1.53% to 1,919.14.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>2.50%</td>
<td>16,708.05</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.67%</td>
<td>5,375.86</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.07%</td>
<td>39,606.57</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.53%</td>
<td>1,919.14</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Acknowledging the swift and often daily shifts in tariff and geopolitical landscapes, Scott Wren, senior global market strategist at Wells Fargo, noted, "With the pace of change on the tariff and geopolitical fronts moving fast and sometimes adjusting on a day-to-day basis, investors are wondering what they might do to help navigate the uncertainties."
To navigate these uncertainties, Wren has advised investors to maintain <a href="https://www.benzinga.com/government/regulations/25/04/44973246/market-dip-attractive-entry-point-says-wells-fargo-energy-large-and-mid-cap-stock-favored">exposure in higher-quality equities</a> and fixed income, emphasizing the need for a plan to withstand market volatility while pursuing growth.
Wren stated, "The first rule of thumb for our plan is to focus on quality in a diversified manner."
Pointing to the stronger balance sheets, dependable cash flows, easy credit access, and share buyback capabilities of larger companies, Wren said, "We continue to favor large- and mid-capitalization equities over small-cap."
Additionally, Wells Fargo favors the energy sector and holds favorable ratings on Information Technology, Financials, and Communication Services, according to Wren, who explained, "We believe these sectors feature long-term growth drivers and robust balance sheets. We suggest investors put funds to work in these sectors at current market levels. In our view, the pullback in stocks offers long-term investors an attractive entry point."
After Trump blasted Fed Chairman Jerome Powell in a Truth Social post on Monday and said that "Powell's termination can't come quickly enough,&#8221; during a Tuesday press conference, he changed his tone, saying, "I have no intention of firing him".
&#8220;Essentially, if there is a recession, President Trump will likely blame Fed Chairman Powell for failing to cut key interest rates fast enough,&#8221; said Louis Navellier of Navellier and Associates.
Talking about the ongoing uncertainty surrounding Trump&#8217;s policies, Ed Yardeni of Yardeni Research said, &#8220;Trump's Tariff Turmoil has put the world on edge. A new world order may be the ultimate result, but for now we've got the New World Disorder, leaving everyone scrambling to adjust to Trump's unpredictable policy pivots. The economic fallout is uncertain. The uncertainty is keeping Wall Street on edge.&#8221;
See Also:<a href="https://www.benzinga.com/money/how-to-trade-futures"> How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul>
<li>Initial jobless claims for the week ended April 19, along with March&#8217;s durable-goods orders data, will be out by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Existing home sales for March will be released by 10:00 a.m., and Minneapolis Fed President Neel Kashkari will speak at 5:00 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) fell 0.19% in premarket on Thursday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $1.49 per share on revenue of $10.70 billion.</li>
</ul>
<ul>
<li>PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) was down 0.11% as Wall Street expects it to report earnings of $1.49 per share on revenue of $17.77 billion before the opening bell.</li>
</ul>
<ul>
<li>Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) declined 0.96% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $1.53 per share on revenue of $20.11 billion.</li>
</ul>
<ul>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) was 0.84% lower as Wall Street expects it to report earnings of $2.02 per share on revenue of $88.87 billion after the closing bell.</li>
</ul>
<ul>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) tumbled 7.91% after posting weaker-than-expected earnings for its first quarter and confirming its guidance for the rest of the year.</li>
</ul>
<ul>
<li>Alaska Air Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) plunged 7.18% after it warned of a slower demand as its second-quarter profit outlook fell short of expectations.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.48% to hover around $62.57 per barrel.
Gold Spot US Dollar rose 1.43% to hover around $3,335.49 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.50% at the 99.3430 level.
Asian markets were mixed on Thursday. Japan's Nikkei 225 and Australia's ASX 200 indices advanced. While Hong Kong's Hang Seng, India's S&amp;P BSE Sensex, China&#8217;s CSI 300, and South Korea's Kospi index fell. European markets were mostly lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44972416/ibm-plays-down-trump-tariff-concerns-doge-could-affect-consulting-business-but-its-us-federal-bu">IBM Plays Down Trump Tariff Concerns: DOGE Could Affect Consulting Business, But Its &#8216;US Federal Business Is Less Than 5%,&#8217; Says CEO</a></li>
</ul>
Image via Shutterstock

Asia

Earnings Misses

Macro Economic Events

Macro Notification

Market Summary

Bonds

Broad U.S. Equity ETFs

Emerging Markets

Futures

Forex

Treasuries

Economics

Federal Reserve

ETFs

GOOG

US Stock Futures Drop Amid Mixed Signals From White House On US-China Trade: 'Focus On Quality In A Diversified Manner,' Says Expert

ADXN

ALEX

AMAL

AMBP

APOG

APPF

BAFN

BCPC

BELFA

BELFB

BFST

BHLB

BWMX

CIVB

CNOB

COUR

CUBI

CURB

DAIO

DGICA

DGICB

FARO

FBIZ

FCFS

FCNCA

FFBC

FRME

GBCI

GLPI

GNFT

HELE

HFWA

IBCP

INDV

ITGR

KNSL

KRNY

LADR

LYTS

MBLY

MGRC

MMSI

MOFG

Earnings Scheduled For April 24, 2025

With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) to report quarterly earnings at $1.49 per share on revenue of $10.70 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Bristol-Myers Squibb shares fell 0.2% to $48.43 in after-hours trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) posted weaker-than-expected earnings for its first quarter and confirmed its guidance for the rest of the year. Nokia shares gained 0.8% to $5.35 in the after-hours trading session.</li>
<li>Analysts are expecting PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) to post quarterly earnings at $1.49 per share on revenue of $17.77 billion. The company will release earnings before the markets open. PepsiCo shares slipped 0.3% to $141.90 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Before the markets open, The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) is projected to report quarterly earnings at $1.53 per share on revenue of $20.11 billion. Procter &amp; Gamble shares fell 0.6% to $164.75 in the after-hours trading session.</li>
<li>Analysts expect Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) to post quarterly earnings at $2.02 per share on revenue of $88.87 billion after the closing bell. Alphabet shares gained 0.4% to $155.89 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

PepsiCo, Alphabet And 3 Stocks To Watch Heading Into Thursday

The CNN Money Fear and Greed index some improvement in market sentiment, with the index in the &#8220;Fear&#8221; zone on Wednesday.
U.S. stocks settled higher on Wednesday, with the Dow Jones index jumping more than 400 points during the session. However, all three major indices closed the session well off their highs as the Dow jumped over 1,100 points at one point during morning session.
On the trade front, tensions with China appeared to thaw, with reports suggesting the White House is considering reducing tariffs on certain categories of goods.
Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) reported better-than-expected first-quarter financial results and raised its FY25 adjusted EPS guidance above estimates. Shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained more than 5% on Wednesday after the company released earnings results for its first quarter.
On the economic data front, sales of new single-family homes in the U.S. jumped by 7.4% to an annualized rate of 724,000. The S&amp;P Global services PMI dipped to 51.4 in April from 54.4 in the prior month. The S&amp;P Global manufacturing PMI climbed to 50.7 in April from 50.2 in the previous month.
Most sectors on the S&amp;P 500 closed on a positive note, with information technology, consumer discretionary and communication services stocks recording biggest gains on Wednesday. However, consumer staples and energy stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 420 points to 39,606.57 on Wednesday. The S&amp;P 500 jumped 1.67% to 5,375.86, while the Nasdaq Composite surged 2.50% at 16,708.05 during Wednesday's session.
Investors are awaiting earnings results from Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) today.
At a current reading of 27.3, the index remained in the &#8220;Fear&#8221; zone on Wednesday, versus a prior reading of 26.2.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based
&nbsp;on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

Dow Jumps Over 400 Points Amid China Tariff Hopes, Investor Fear Eases: Greed Index Remains In 'Fear' Zone

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec

Evotec Deepens CELMoDs Alliance With Bristol Myers Squibb As Molecular Glue Degrader Pipeline Expands

Cantor Fitzgerald analyst Carter Gould reiterates Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral and maintains $55 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $55 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) price target from $67 to $70. Evercore ISI Group analyst David Palmer maintained an Outperform rating. Mondelez shares closed at $68.29 on Tuesday. <a href="https://www.benzinga.com/quote/MDLZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) from $160 to $164. Barclays analyst Julian Mitchell maintained an Overweight rating. 3M shares closed at $136.33 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/MMM/analyst-ratings">view this stock</a>.</li>
<li>Jefferies cut Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) price target from $70 to $68. Jefferies analyst Akash Tewari maintained a Buy rating. Bristol-Myers Squibb shares closed at $49.82 on Tuesday. See how other analysts view<a href="https://www.benzinga.com/quote/BMY/analyst-ratings"> this stock</a>.</li>
<li>Canaccord Genuity cut the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $404 to $303. Canaccord Genuity analyst George Gianarikas maintained a Buy rating. Tesla shares closed at $237.97 on Tuesday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted the price target for FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>) from $42 to $45. B of A Securities analyst Julien Dumoulin-Smith upgraded the stock from Underperform to Neutral. FirstEnergy shares closed at $42.71 on Tuesday. <a href="https://www.benzinga.com/quote/FE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Moody&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) price target from $575 to $525. Baird analyst Jeffrey Meuler maintained an Outperform rating. Moody&#8217;s shares settled at $429.87 on Tuesday. <a href="https://www.benzinga.com/quote/MCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic slashed American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) price target from $270 to $255. Redburn Atlantic analyst Harry Bartlett upgraded the stock from Sell to Neutral. American Express shares closed at $252.42 on Tuesday. <a href="https://www.benzinga.com/quote/AXP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Redburn Atlantic cut Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) price target from $156 to $124. Redburn Atlantic analyst Peter Low downgraded the stock from Neutral to Sell. Chevron shares closed at $137.30 on Tuesday.  <a href="https://www.benzinga.com/quote/CVX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Murphy Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) from $32 to $24. Barclays analyst Betty Jiang downgraded the stock from Equal-Weight to Underweight. Murphy Oil shares settled at $21.39 on Tuesday. <a href="https://www.benzinga.com/quote/MUR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group slashed Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $275 to $235. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Amazon shares closed at $173.18 on Tuesday. <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23095655/image-1-26-1024x576.png" alt="" class="wp-image-884299" style="width:519px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23095655/image-1-26-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23095655/image-1-26-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23095655/image-1-26-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23095655/image-1-26.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44920101/top-2-tech-and-telecom-stocks-you-may-want-to-dump-this-quarter">Top 2 Tech And Telecom Stocks You May Want To Dump This Quarter</a> </li>
</ul>
Photo via Shutterstock

MDLZ

Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday

Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of&nbsp;Cobenfy&nbsp;(xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia.
In the Phase 3 trial, adjunctive&nbsp;Cobenfy&nbsp;treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsychotic at Week 6, which did not reach the threshold for statistical significance for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44936890/bristol-myers-squibb-announces-topline-results-from-phase-3-arise-trial-evaluating-cobenfy-xanomel" rel="noreferrer noopener">primary endpoint (P = 0.11)</a>.
PANSS is used to assess the severity of positive and negative symptoms. It measures symptoms like hallucinations, delusions, and disorganized thinking, as well as negative symptoms like blunted affect and social withdrawal.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach</a>
Preliminary analyses suggest that&nbsp;Cobenfy&nbsp;as an adjunctive treatment to an atypical antipsychotic was associated with improvements in symptoms of schizophrenia compared to placebo plus an atypical antipsychotic for certain patients.
In a post-hoc subgroup analysis, there was a notable difference in response between subjects treated with risperidone as a background therapy compared with the remaining subjects treated with other background antipsychotics (non-risperidone).
Cobenfy's safety and tolerability profile as an adjunctive treatment was consistent with previous monotherapy trials.
Bristol Myers Squibb will complete a full evaluation of the Phase 3 trial data and intends to present detailed results at an upcoming medical conference.
In September 2024, the FDA approved&nbsp;Cobenfy, an oral medication for&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41073709/absence-of-black-box-warning-for-bristol-myers-schizophrenia-treatment-could-enhanc" rel="noreferrer noopener">schizophrenia in adults</a>.
Data from the EMERGENT clinical program supported the FDA approval of Cobenfy. In Phase 3 EMERGENT-2 and EMERGENT-3 trials, Cobenfy met its primary endpoint, demonstrating statistically significant reductions of schizophrenia symptoms compared to placebo from baseline to week five.
William Blair viewed "the ARISE trial as one that could accelerate the uptake of Cobenfy overall, increasing physician confidence in the adjunctive setting ahead of their own personalized approaches."
Even though this setback might lower the chances of strong short-term results, Analyst Matt Phipps still sees a big long-term potential for Cobenfy, with estimated global sales reaching $3.7 billion for schizophrenia.
Bristol is expected to report first-quarter earnings on Thursday, April 24 and it is expected management to provide additional details on the study's impact to the launch curve for Cobenfy and longer-term opportunity.
"The opportunity in Alzheimer's disease psychosis is the next key readout for Cobenfy, where we see significant market opportunity assuming clinical success and a tolerable safety profile," analyst Phipps writes.
In November 2024, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the PANSS total score compared to the placebo group at week 6.
Last year, Leerink analyst estimated the potential for peak Cobenfy sales of over $10 billion if it succeeds in additional indications since&nbsp;Eli Lilly And Co's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zyprexa generated $5 billion in peak revenue in 2010 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock" rel="noreferrer noopener">at much lower prices</a>.
Price Action: BMY stock is down 2.95% at $48.35 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44938762/draftkings-may-trim-2025-forecast-amid-texas-jackpocket-shutdown-says-analyst" target="_blank" rel="noreferrer noopener">DraftKings May Trim 2025 Forecast Amid Texas Jackpocket Shutdown: Analyst</a></li>
</ul>
Photo via Shutterstock

ABBV

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

Jefferies analyst Akash Tewari maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Buy and lowers the price target from $70 to $68.

Jefferies Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $68

Press Releases

Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for the Third Consecutive Year

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol Myers Squibb Reports First Quarter Financial Results for 2025

Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

Comments

Bristol-Myers Squibb

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌